Our core strategies include (i) the development, manufacturing and sales of the WatchPAT™ diagnostic product line based on the biological PAT® signal acquired by the PAT® technology that was proven as a simple, comprehensive, reliable and scalable alternative to airflow and it enables point-of-deployment versatility; and (ii) Total Sleep Solutions – a product that includes a field support organization, partnerships, as well as core and supporting technologies that enable all physicians in general and Cardiologists in particular to provide a seamless and full continuum of care to Sleep Apnea patients as part of their care pathway.
In addition, the company has developed and is currently marketing the EndoPAT™ system – an endothelial function assessment tool for risk classification used by clinicians, researchers and pharma companies to easily and reliably quantify and track arterial health.
Itamar Medical, in collaboration with leading sleep physicians and industry partners, has pioneered a novel cross-disciplinary model of care developed for the integration of Sleep Apnea management into cardiac patients care pathway. TSS expands the reach of sleep services by enabling point of care variability, providing a scalable model for management of a massive volume of patients’ while reducing wait times and overall cost, and offering optimized IT systems and human field resources to support the vast underdiagnosed pool of cardiac patients suffering from the co-morbidity of Sleep Apnea.
Providing a scalable model for management
An innovative FDA-cleared device for the diagnosis of sleep breathing disorders, specifically Sleep Apnea. It is a small wrist mounted device which allows testing in the comfort of the patient’s own home.
During the past few years, Itamar Medical has signed a number of strategic marketing agreements for
its products, including agreements with Medtronic, Philips, Resmed, and SoClean in the US, and Philips Respironics and in Japan.
Its proprietary technology enables the non-invasive recording, measurement and analysis of Peripheral Arterial Tonometry, or the PAT signal. The PAT signal measures changes in a patient’s pulsatile arterial volume, providing a “window” to the cardiovascular system and the sympathetic branch of the autonomic nervous system.
To be the world leader in providing complete sleep solutions to cardiac patients.
World Leader in Sleep Apnea Management Solutions with a Focus on Additional Care Pathways.
On a Mission to Address the 80% Undiagnosed and Untreated through Digital Health Platform.
The corporate headquarters, R&D, and manufacturing for Itamar Medical Ltd. are located in Israel. The company markets, services and supports its products worldwide. Itamar Medical has wholly-owned subsidiaries in the U.S. and Japan and distribution channels around the world.